Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

f Ambit's drug development programs, including the submission of regulatory filings and planned discussions with regulatory bodies, plans regarding future clinical trials of quizartinib and Ambit's other drug candidates, the progress and expected timing of clinical trials, the presentation of data from clinical trials, the clinical benefits to be derived from quizartinib and Ambit's other drug candidates, the regulatory approval path for quizartinib, the strength of Ambit's balance sheet and adequacy of cash on hand, and Ambit's financial guidance.. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as  "plans," "expects," "anticipates," "hopes", "may," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Ambit's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Ambit's programs are described in additional detail in Ambit's SEC filings. All forward-looking statements contained in this press release speak only as of the date on which they were made. Ambit undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

  Ambit Biosciences CorporationSelected Financial Information Condensed Consolidated Statements of Operations(unaudited, in thou
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Edwardsville, Ill. (PRWEB) October 31, 2014 ... Edwardsville’s Department of Historical Studies within the College of ... at SIUE to record the history of alcohol-based fuels ... politicians, and many others have been working to build ... an important but overlooked aspect of the state's agricultural ...
(Date:10/31/2014)... The report "Dairy Alternative (Beverage) Market ... Sweetened, Unsweetened), Channel (Supermarket, Health Store, Pharmacy, Convenience ... to 2018," defines and segments the dairy alternative ... revenue and volume for plant-based dairy alternative beverages. ... $14 Billion by 2018 with the Asia-Pacific region ...
(Date:10/31/2014)... New York, NY (PRWEB) October 31, 2014 ... sectors such as healthcare, construction, finance and consumer ... applications. For this reason, industry research firm IBISWorld ... Software industry to its growing industry report collection. ... that develop software for biometric technologies such as ...
(Date:10/30/2014)... The report “Fragrance Ingredients Market by Type (Essential ... and Soaps & Detergents) & by Geography - Global ... the Fragrance Ingredients Market with analyses and projection of ... market has been segmented on the basis of major ... and Rest of the World (ROW); and their value ...
Breaking Biology Technology:SIUE History Prof Manuel Working on Biofuels Book with NCERC 2SIUE History Prof Manuel Working on Biofuels Book with NCERC 3Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 2Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 3Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 4Biometrics Scan Software in the US Industry Market Research Report Now Available from IBISWorld 2Biometrics Scan Software in the US Industry Market Research Report Now Available from IBISWorld 3Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 2Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 3Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 4Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 5
... Expedites Reporting Process, WALL, N.J., Oct. 24 ... leader in wireless public safety,solutions and finger based ... from the Littleton, Colorado Police Department,to implement the ... is a module of BIO-key,s Mobile Office(TM) solution. ...
... SAN FRANCISCO, Oct. 24 Cell Therapeutics,Inc. ... data presented at,the 19th annual AACR-NCI-EORTC Symposium ... kill tumors refractory to currently,marketed platinum agents ... human clinical trials in late 2008. ...
... (Nasdaq: KERX ) will hold a conference call ... discuss the Third Quarter 2007 financial results.,Michael S. Weiss, ... the call. Keryx will announce its financial results for ... to the call. In order to participate in ...
Cached Biology Technology:BIO-key(R) Awarded Contract to Deploy Incident Reporting System for Littleton, CO Police Department 2First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs 2First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs 3Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT 2
(Date:10/30/2014)... German . ... to behave socially? This is one of the central ... studies assumed that it is almost impossible to control ... Planck Institute for Evolutionary Biology have now demonstrated that ... cooperative behaviour of others. However, the possibilities available to ...
(Date:10/30/2014)... 29, 2014  Securus Technologies, a leading ... solutions for public safety, investigation, corrections and ... exciting enhancements to its THREADS™ product, which ... actionable intelligence and focused leads for investigators. ... technological innovation through identifying and delivering solutions ...
(Date:10/29/2014)... open for the Society of Interventional Radiology,s ... is the one place where interventional radiologists, ... care professionals can come together to find ... being presented, discussed and tested. , ... image-guided medicine, SIR 2015 will feature essential ...
Breaking Biology News(10 mins):Together we are strong -- or insufferable 2Together we are strong -- or insufferable 3Together we are strong -- or insufferable 4Securus Technologies Adds Advanced Features to Its Industry-Leading Investigative Analytics Product 2SIR 2015: Interventional radiology shapes tomorrow's medicine 2
... Tenn. Consider the case of the three-spine stickleback. ... fresh water might appear to be the same, yet ... collection of very specialized individuals. Understanding the ... the goal of a group of scientists meeting at ...
... Stephania Cormier, PhD, Associate Professor of Pharmacology ... shown for the first time that early exposure ... ultrafine particulate matter) affects long-term lung function. She ... 11th International Congress on Combustion By-Products and Their ...
... research that allows farmers to harvest rice earlier, giving them ... needed food and ease hunger during monga -- the hunger ... northwest Bangladesh from September to November after the previous season,s ... rice in December. According to the Bangladesh Bureau ...
Cached Biology News:The value of variation: Ecologists consider the causes and consequences 2LSUHSC shows for first time infant inhalation of ultrafine air pollution linked to adult lung disease 2Early rice harvests ease annual famine in Bangladesh 2
... to detect the appearance of AcNPV gp64 ... as early as 8-24 hours post-infection. This ... Kit, which allows determination of baculovirus titers ... FastPlax Antibody can also be used to ...
synaptotagmin XIV-like [Source:RefSeq_peptide;Acc:NP_114120] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Goat polyclonal to SIAH Interacting Protein ( Abpromise for all tested applications)....
MAb to Transferrin Dry Ice: No Preservative: NaN3 Availability When Not in Inventory: 14-21 Business Days...
Biology Products: